In Vivo Administration of a JAK3 Inhibitor during Acute SIV Infection Leads to Significant Increases in Viral Load during Chronic Infection

PLoS Pathogens

Volumn 10, Issue 3, 2014, Pages

  Takahashi, Yoshiaki ^a   Byrareddy, Siddappa N ^a   Albrecht, Christina ^b   Brameier, Markus ^b   Walter, Lutz ^b   Mayne, Ann E ^a   Dunbar, Paul ^a   Russo, Robert ^a   Little, Dawn M ^a   Villinger, Tara ^a   Khowawisetsut, Ladawan ^c   Pattanapanyasat, Kovit ^c   Villinger, Francois ^a,d   Ansari, Aftab A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERMAN PRIMATE CENTER   (Germany)

^c MAHIDOL UNIVERSITY   (Thailand)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; JANUS KINASE 3 INHIBITOR; NEUTRALIZING ANTIBODY; TOFACITINIB;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; GASTROINTESTINAL TRACT; LYMPHOID CELL; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; RECTUM BIOPSY; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS LOAD;

ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; JANUS KINASE 3; KILLER CELLS, NATURAL; MACACA MULATTA; PIPERIDINES; PYRIMIDINES; PYRROLES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRAL LOAD;

EID: 84897416431     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003929     Document Type: Article

References (110)

1. Ansari AA, Mayne AE, Takahashi Y, Pattanapanyasat K, (2011) Incorporation of innate immune effector mechanisms in the formulation of a vaccine against HIV-1. Adv Exp Med Biol 780: 143-159.
2. Caligiuri MA, (2008) Human natural killer cells. Blood 112: 461-469.
3. Haase AT, (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
4. Alter G, Altfeld M, (2011) Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection. Trends Immunol 32: 219-224 doi: 210.1016/j.it.2011.1002.1003. Epub 2011 Mar 1014.
5. Borrow P, Alter G, Altfeld M, (2011) Innate immunity in acute HIV-1 infection. Curr Opin HIV AIDS 6: 353-363.
6. Welsh RM, Waggoner SN, Borrow P, Alter G, Altfeld M, (2013) NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent infections. Virology 435: 37-45.
7. Bezman NA, Chakraborty T, Bender T, Lanier LL, (2011) miR-150 regulates the development of NK and iNKT cells. J Exp Med 208: 2717-2731.
8. Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, et al. (2009) Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 10: 66-74.
9. Eissens DN, Spanholtz J, van der Meer A, van Cranenbroek B, Dolstra H, et al. (2012) Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS One 7: e30930.
10. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, et al. (2006) Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 203: 1033-1043.
11. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, et al. (2007) The trafficking of natural killer cells. Immunol Rev 220: 169-182.
12. Haraguchi K, Suzuki T, Koyama N, Kumano K, Nakahara F, et al. (2009) Notch activation induces the generation of functional NK cells from human cord blood CD34-positive cells devoid of IL-15. J Immunol 182: 6168-6178.
13. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, et al. (2009) IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 206: 25-34.
14. Kamizono S, Duncan GS, Seidel MG, Morimoto A, Hamada K, et al. (2009) Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med 206: 2977-2986.
15. Li N, Puga Yung GL, Pradier A, Toso C, Giostra E, et al. (2013) NK cell isolation from liver biopsies: phenotypic and functional analysis of low cell numbers by flow cytometry. Front Immunol 4: 61.
16. Pereira LE, Johnson RP, Ansari AA, (2008) Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. Cell Immunol 254: 10-19.
17. Reeves RK, Rajakumar PA, Evans TI, Connole M, Gillis J, et al. (2011) Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood 118: 3321-3330.
18. Sun JC, Lanier LL, (2011) NK cell development, homeostasis and function: parallels with CD8(+) T cells. Nat Rev Immunol 11: 645-657.
19. Vargas CL, Poursine-Laurent J, Yang L, Yokoyama WM, (2011) Development of thymic NK cells from double negative 1 thymocyte precursors. Blood 118: 3570-3578.
20. Krueger PD, Lassen MG, Qiao H, Hahn YS, (2011) Regulation of NK cell repertoire and function in the liver. Crit Rev Immunol 31: 43-52.
21. Paust S, Gill HS, Wang BZ, Flynn MP, Moseman EA, et al. (2010) Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 11: 1127-1135.
22. Xu H, Wang X, Liu DX, Moroney-Rasmussen T, Lackner AA, et al. (2012) IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol 5: 658-669.
23. Cooper MA, Yokoyama WM, (2010) Memory-like responses of natural killer cells. Immunol Rev 235: 297-305.
24. Deniz G, Erten G, Kucuksezer UC, Kocacik D, Karagiannidis C, et al. (2008) Regulatory NK cells suppress antigen-specific T cell responses. J Immunol 180: 850-857.
25. Ehlers M, Papewalis C, Stenzel W, Jacobs B, Meyer KL, et al. (2012) Immunoregulatory natural killer cells suppress autoimmunity by down-regulating antigen-specific CD8+ T cells in mice. Endocrinology 153: 4367-4379.
26. Fauriat C, Long EO, Ljunggren HG, Bryceson YT, (2010) Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 115: 2167-2176.
27. Fu B, Li X, Sun R, Tong X, Ling B, et al. (2013) Natural killer cells promote immune tolerance by regulating inflammatory TH17 cells at the human maternal-fetal interface. Proc Natl Acad Sci U S A 110: E231-240.
28. Ge MQ, Ho AW, Tang Y, Wong KH, Chua BY, et al. (2012) NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza A infection by IFN-gamma and perforin-dependent mechanisms. J Immunol 189: 2099-2109.
29. Jewett A, Man YG, Tseng HC, (2013) Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J Cancer 4: 12-24.
30. Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, et al. (2012) Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A 109: 1210-1215.
31. Paust S, von Andrian UH, (2011) Natural killer cell memory. Nat Immunol 12: 500-508.
32. Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, et al. (2012) Cytokine activation induces human memory-like NK cells. Blood 120: 4751-4760.
33. Strowig T, Brilot F, Munz C, (2008) Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 180: 7785-7791.
34. Waggoner SN, Cornberg M, Selin LK, Welsh RM, (2012) Natural killer cells act as rheostats modulating antiviral T cells. Nature 481: 394-398.
35. Zhang T, Scott JM, Hwang I, Kim S, (2013) Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcRgamma Deficiency. J Immunol 190: 1402-1406.
36. Elliott JM, Yokoyama WM, (2011) Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 32: 364-372.
37. Hosoya S, Ikejima K, Takeda K, Arai K, Ishikawa S, et al. (2013) Innate immune responses involving natural killer and natural killer T cells promote liver regeneration after partial hepatectomy in mice. Am J Physiol Gastrointest Liver Physiol 304: G293-299.
38. Jonsson AH, Yokoyama WM, (2009) Natural killer cell tolerance licensing and other mechanisms. Adv Immunol 101: 27-79.
39. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, et al. (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.
40. Kumar P, Rajasekaran K, Palmer JM, Thakar MS, Malarkannan S, (2013) IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration. J Cancer 4: 57-65.
41. Mace EM, Orange JS, (2012) New views of the human NK cell immunological synapse: recent advances enabled by super- and high-resolution imaging techniques. Front Immunol 3: 421.
42. Murphy WJ, Parham P, Miller JS, (2012) NK cells-from bench to clinic. Biol Blood Marrow Transplant 18: S2-7.
43. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, et al. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
44. Takahashi Y, Mayne AE, Khowawisetsut L, Pattanapanyasat K, Little D, et al. (2013) In Vivo Administration of a JAK3 Inhibitor to Chronically SIV Infected Rhesus Macaques Leads to NK Cell Depletion Associated with Transient Modest Increase in Viral Loads. PLoS One 8: e70992 doi: 70910.71371/journal.pone.0070992. Print 0072013.
45. Paniagua R, Si MS, Flores MG, Rousvoal G, Zhang S, et al. (2005) Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 80: 1283-1292.
46. Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, et al. (2008) The specificity of JAK3 kinase inhibitors. Blood 111: 2155-2157 Epub 2007 Dec 2119.
47. Kiu H, Nicholson SE, (2012) Biology and significance of the JAK/STAT signalling pathways. Growth Factors 30: 88-106 doi: 110.3109/08977194.08972012.08660936. Epub 08972012 Feb 08977120.
48. O'Shea JJ, Plenge R, (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36: 542-550.
49. Simmons DL, (2013) Targeting kinases: a new approach to treating inflammatory rheumatic diseases. Curr Opin Pharmacol 13: 426-434 doi: 410.1016/j.coph.2013.1002.1008. Epub 2013 Mar 1019.
50. Soth M, Hermann JC, Yee C, Alam M, Barnett JW, et al. (2013) 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models. J Med Chem 56: 345-356 doi: 310.1021/jm301646k. Epub 302012 Dec 301619.
51. Allen PB, Peyrin-Biroulet L, (2013) Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol 29: 397-404 doi: 310.1097/MOG.1090b1013e3283622914.
52. Cottone M, Orlando A, Papi C, (2012) Tofacitinib in active ulcerative colitis. N Engl J Med 367: 1960 author reply 1960-1961. doi: #1910.1056/NEJMc1211073#SA1211072.
53. Garber K, (2013) Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol 31: 3-4 doi: 10.1038/nbt0113-1033.
54. Gremese E, Ferraccioli G, (2013) Tofacitinib for rheumatoid arthritis. Lancet 381: 1812 doi: 1810.1016/S0140-6736(1813)61114-61119.
55. Ansari AA, Reimann KA, Mayne AE, Takahashi Y, Stephenson ST, et al. (2011) Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 186: 1044-1059.
56. Paniagua R, Campbell A, Changelian PS, Reitz BA, Prakash C, et al. (2005) Quantitative analysis of the immunosuppressant CP-690,550 in whole blood by column-switching high-performance liquid chromatography and mass spectrometry detection. Ther Drug Monit 27: 608-616.
57. Moreland AJ, Guethlein LA, Reeves RK, Broman KW, Johnson RP, et al. (2011) Characterization of killer immunoglobulin-like receptor genetics and comprehensive genotyping by pyrosequencing in rhesus macaques. BMC Genomics 12:29510.1186/1471-2164-1112-1295.
58. O'Leary CE, Wiseman RW, Karl JA, Bimber BN, Lank SM, et al. (2009) Identification of novel MHC class I sequences in pig-tailed macaques by amplicon pyrosequencing and full-length cDNA cloning and sequencing. Immunogenetics 61: 689-701 doi: 610.1007/s00251-00009-00397-00254. Epub 02009 Sep 00224.
59. Bixby JG, Laur O, Johnson WE, Desrosiers RC, (2010) Diversity of envelope genes from an uncloned stock of SIVmac251. AIDS Res Hum Retroviruses 26: 1115-1131 doi: 1110.1089/aid.2010.0029. Epub 2010 Sep 1113.
60. Alpert MD, Heyer LN, Williams DE, Harvey JD, Greenough T, et al. (2012) A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J Virol 86: 12039-12052 doi: 12010.11128/JVI.01650-12012. Epub 12012 Aug 12029.
61. Kottilil S, Jackson JO, Reitano KN, O'Shea MA, Roby G, et al. (2007) Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. J Acquir Immune Defic Syndr 46: 151-159.
62. Khowawisetsut L, Pattanapanyasat K, Onlamoon N, Mayne AE, Little DM, et al. (2013) Relationships between IL-17+ subsets, Tregs and pDCs that distinguish among SIV infected elite controllers, low, medium and high viral load rhesus macaques1. PlosOne 8 (7) (): e70992.
63. Kwa S, Kannanganat S, Nigam P, Siddiqui M, Shetty RD, et al. (2011) Plasmacytoid dendritic cells are recruited to the colorectum and contribute to immune activation during pathogenic SIV infection in rhesus macaques. Blood 118: 2763-2773 doi: 2710.1182/blood-2011-2702-339515. Epub 332011 Jun 339521.
64. Reeves RK, Evans TI, Gillis J, Wong FE, Kang G, et al. (2012) SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa. J Infect Dis 206: 1462-1468 doi: 1410.1093/infdis/jis1408. Epub 2012 Jun 1418.
65. Funke J, Durr R, Dietrich U, Koch J, (2011) Natural killer cells in HIV-1 infection: a double-edged sword. AIDS Rev 13: 67-76.
66. Jost S, Altfeld M, (2013) Control of Human Viral Infections by Natural Killer Cells. Annu Rev Immunol 31: 163-94.
67. Kottilil S, Shin K, Jackson JO, Reitano KN, O'Shea MA, et al. (2006) Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol 176: 1107-1114.
68. Pallikkuth S, Parmigiani A, Pahwa S, (2012) Role of IL-21 and IL-21 receptor on B cells in HIV infection. Crit Rev Immunol 32: 173-195.
69. Borie DC, O'Shea JJ, Changelian PS, (2004) JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 10: 532-541.
70. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132 doi: 110.1038/nbt1358.
71. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, et al. (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186: 4234-4243 doi: 4210.4049/jimmunol.1003668. Epub 1002011 Mar 1003667.
72. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, et al. (1995) Defective lymphoid development in mice lacking Jak3. Science 270: 800-802.
73. O'Shea JJ, Husa M, Li D, Hofmann SR, Watford W, et al. (2004) Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 41: 727-737.
74. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A, (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72: ii111-115 doi: 110.1136/annrheumdis-2012-202576.
75. Yoshida H, Kimura A, Fukaya T, Sekiya T, Morita R, et al. (2012) Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochem Biophys Res Commun 418: 234-240 doi: 210.1016/j.bbrc.2011.1012.1156. Epub 2012 Jan 1019.
76. Fleischmann R, (2012) Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 24: 335-341 doi: 310.1097/BOR.1090b1013e32835190ef.
77. Garber K, (2011) Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol 29: 467-468 doi: 410.1038/nbt0611-1467.
78. Kontzias A, Laurence A, Gadina M, O'Shea JJ, (2012) Kinase inhibitors in the treatment of immune-mediated disease. 1000 4:5.: 10.3410/M3414-3415. Epub 2012 Mar 3411.
79. Ahmad A, Ahmad R, Iannello A, Toma E, Morisset R, et al. (2005) IL-15 and HIV infection: lessons for immunotherapy and vaccination. Curr HIV Res 3: 261-270.
80. Bostik P, Takahashi Y, Mayne AE, Ansari AA, (2010) Innate immune natural killer cells and their role in HIV and SIV infection. HIV Ther 4: 483-504.
81. Inngjerdingen M, Kveberg L, Naper C, Vaage JT, (2011) Natural killer cell subsets in man and rodents. Tissue Antigens 78: 81-88 doi: 10.1111/j.1399-0039.2011.01714.x.
82. Verbist KC, Klonowski KD, (2012) Functions of IL-15 in anti-viral immunity: multiplicity and variety. Cytokine 59: 467-478 doi: 410.1016/j.cyto.2012.1005.1020. Epub 2012 Jun 1015.
83. Degottardi M, Okoye A, Rohinkedkar M, Konfe A, Turner J, et al. (2012) Understasnding the role of IL-15 in SIV pathogenesis. Nonhuman Primate Meetings. San Antonio, TX.
84. Schmitz JE, Johnson RP, McClure HM, Manson KH, Wyand MS, et al. (2005) Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol 79: 8131-8141.
85. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857-860.
86. Coskun M, Salem M, Pedersen J, Nielsen OH, (2013) Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 76C: 1-8 10.1016/j.phrs.2013.1006.1007.
87. Kawalec P, Mikrut A, Wisniewska N, Pilc A, (2013) The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 23: 23.
88. Yokoyama S, Perera PY, Waldmann TA, Hiroi T, Perera LP, (2013) Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol 33: 586-594 doi: 510.1007/s10875-10012-19849-y. Epub 12012 Dec 10828.
89. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, et al. (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367: 616-624 doi: 610.1056/NEJMoa1112168.
90. Agace WW, (2008) T-cell recruitment to the intestinal mucosa. Trends Immunol 29: 514-522 doi: 510.1016/j.it.2008.1008.1003.
91. Cimbro R, Vassena L, Arthos J, Cicala C, Kehrl JH, et al. (2012) IL-7 induces expression and activation of integrin alpha4beta7 promoting naive T-cell homing to the intestinal mucosa. Blood 120: 2610-2619 Epub 2012 Aug 2614.
92. De Calisto J, Villablanca EJ, Wang S, Bono MR, Rosemblatt M, et al. (2012) T-cell homing to the gut mucosa: general concepts and methodological considerations. Methods Mol Biol 757: 411-34 10.1007/1978-1001-61779-61166-61776_61724.
93. Perez-Villar JJ, Zapata JM, Melero I, Postigo A, Sanchez-Madrid E, et al. (1996) Expression and function of alpha 4/beta 7 integrin on human natural killer cells. Immunology 89: 96-104.
94. Jost S, Moreno-Nieves UY, Garcia-Beltran WF, Rands K, Reardon J, et al. (2013) Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection. Retrovirology 10: 74 doi: 10.1186/1742-4690-1110-1174.
95. Micci L, Cervasi B, Ende ZS, Iriele RI, Reyes-Aviles E, et al. (2012) Paucity of IL-21-producing CD4(+) T cells is associated with Th17 cell depletion in SIV infection of rhesus macaques. Blood 120: 3925-3935 doi: 3910.1182/blood-2012-3904-420240. Epub 422012 Sep 420218.
96. Paiardini M, Cervasi B, Reyes-Aviles E, Micci L, Ortiz AM, et al. (2011) Low levels of SIV infection in sooty mangabey central memory CD(4)(+) T cells are associated with limited CCR5 expression. Nat Med 17: 830-836 doi: 810.1038/nm.2395.
97. Gorry PR, Ancuta P, (2011) Coreceptors and HIV-1 pathogenesis. Curr HIV/AIDS Rep 8: 45-53 doi: 10.1007/s11904-11010-10069-x.
98. Kader M, Wang X, Piatak M, Lifson J, Roederer M, et al. (2009) Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2: 439-449 doi: 410.1038/mi.2009.1090. Epub 2009 Jul 1031.
99. Martinelli E, Veglia F, Goode D, Guerra-Perez N, Aravantinou M, et al. (2013) The frequency of alpha4beta7high memory CD4+ T cells correlates with susceptibility to rectal SIV infection. J Acquir Immune Defic Syndr 21: 21.
100. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr, et al. (2012) ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8: e1002890 doi: 1002810.1001371/journal.ppat.1002890. Epub 1002012 Aug 1002823.
101. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, et al. (2012) Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86: 11521-11532 doi: 11510.11128/JVI.01023-11512. Epub 12012 Aug 11515.
102. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I, (2008) The utility of ADCC responses in HIV infection. Curr HIV Res 6: 515-519.
103. Wren LH, Stratov I, Kent SJ, Parsons MS, (2013) Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses. Vaccine 24: 01126-01122.
104. Feldman S, Stein D, Amrute S, Denny T, Garcia Z, et al. (2001) Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol 101: 201-210.
105. Malleret B, Maneglier B, Karlsson I, Lebon P, Nascimbeni M, et al. (2008) Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 112: 4598-4608 doi: 4510.1182/blood-2008-4506-162651. Epub 162008 Sep 162611.
106. Hotter D, Sauter D, Kirchhoff F, (2013) Emerging Role of the Host Restriction Factor Tetherin in Viral Immune Sensing. J Mol Biol 26: 029.
107. Carrington M, Alter G, (2012) Innate immune control of HIV. Cold Spring Harb Perspect Med 2: a007070 doi: 007010.001101/cshperspect.a007070.
108. Cunningham AL, Harman A, Kim M, Nasr N, Lai J, (2013) Immunobiology of dendritic cells and the influence of HIV infection. Adv Exp Med Biol 762: 1-44 10.1007/1978-1001-4614-4433-1006_1001.
109. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF, (2012) NK cells: key to success of DC-based cancer vaccines? Oncologist 17: 1256-1270 doi: 1210.1634/theoncologist.2011-0122. Epub 2012 Aug 1220.
110. Pembroke TP, Gallimore AM, Godkin A, (2013) Rapid innate control of antigen abrogates adaptive immunity. Immunology 138: 293-297 doi: 210.1111/imm.12048.